| P50 | author | Miguel Caballero | Q56865107 |
| P2093 | author name string | A. Cardesa | |
| | A. Diaz | |
| | A. Valera | |
| | A. Nadal | |
| | M. Carrera | |
| | S. Hakim | |
| | S. Moyano | |
| | L. Alos | |
| | B. Lujan | |
| P2860 | cites work | Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland | Q28208406 |
| | EGFR antagonists in cancer treatment | Q29616740 |
| | Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors | Q33767107 |
| | EGFR and cancer prognosis | Q34399312 |
| | Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. | Q34536780 |
| | Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer | Q34557318 |
| | Erlotinib in lung cancer - molecular and clinical predictors of outcome | Q34559274 |
| | Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib | Q34678882 |
| | Signaling through the epidermal growth factor receptor during the development of malignancy | Q35729447 |
| | Extra-cellular signal-regulated ERK-1/ERK-2 pathway activation in human salivary gland mucoepidermoid carcinoma: association to aggressive tumor behavior and tumor cell proliferation | Q35791891 |
| | Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition | Q35817494 |
| | An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents | Q35972249 |
| | Epidermal growth factor receptor biology in head and neck cancer | Q36500973 |
| | Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma | Q36755219 |
| | Epidermal growth factor receptor kinase domain mutations are rare in salivary gland carcinomas | Q37123445 |
| | Treatment and survival outcomes based on histologic grading in patients with head and neck mucoepidermoid carcinoma | Q37249560 |
| | Cetuximab in the treatment of metastatic mucoepidermoid carcinoma of the salivary glands: a case report and review of literature. | Q37282841 |
| | Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study. | Q37364638 |
| | Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands | Q38459633 |
| | Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis | Q38482518 |
| | Signal transduction through MAP kinase cascades | Q41750250 |
| | MUC1, MUC2, MUC4, and MUC5AC expression in salivary gland mucoepidermoid carcinoma: diagnostic and prognostic implications | Q43416820 |
| | Mucoepidermoid carcinoma of the lung, response to EGFR inhibitors, EGFR and K-RAS mutations, and differential diagnosis | Q43637446 |
| | Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments | Q43719931 |
| | Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. | Q44024840 |
| | Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer | Q44219909 |
| | Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study | Q46585165 |
| | Epidermal growth factor receptor and human epidermal growth receptor 2 expression in parotid mucoepidermoid carcinoma: possible implications for targeted therapy. | Q46802896 |
| | Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment | Q46810455 |
| | Adenosquamous carcinoma of the head and neck: criteria for diagnosis in a study of 12 cases. | Q47971610 |
| | Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. | Q53479014 |
| | Salivary neoplasms: overview of a 35-year experience with 2,807 patients | Q69592327 |
| | H-ras gene mutations in salivary gland mucoepidermoid carcinomas | Q73388414 |
| | Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study | Q73783125 |
| | ras gene mutations in salivary gland tumors | Q73843957 |
| | Mucoepidermoid carcinoma of the major salivary glands: clinical and histopathologic analysis of 234 cases with evaluation of grading criteria | Q74404908 |
| | Identical epidermal growth factor receptor mutations in adenocarcinomatous and squamous cell carcinomatous components of adenosquamous carcinoma of the lung | Q79448974 |
| | Transforming growth factor alpha dependent cancer progression is modulated by Muc1 | Q80635833 |
| | Epidermal growth factor receptor gene copy number and clinical outcome of metastatic colorectal cancer treated with panitumumab | Q80704675 |
| | Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands | Q81753319 |
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 510-516 | |
| P577 | publication date | 2010-07-27 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Activation of the EGFR/ERK pathway in high-grade mucoepidermoid carcinomas of the salivary glands | |
| P478 | volume | 103 | |